RU2017132689A - СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE - Google Patents

СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE Download PDF

Info

Publication number
RU2017132689A
RU2017132689A RU2017132689A RU2017132689A RU2017132689A RU 2017132689 A RU2017132689 A RU 2017132689A RU 2017132689 A RU2017132689 A RU 2017132689A RU 2017132689 A RU2017132689 A RU 2017132689A RU 2017132689 A RU2017132689 A RU 2017132689A
Authority
RU
Russia
Prior art keywords
fusion protein
high affinity
ige receptor
amino acid
acid sequence
Prior art date
Application number
RU2017132689A
Other languages
English (en)
Other versions
RU2715606C2 (ru
RU2017132689A3 (ru
Inventor
Такаси САКАМОТО
Йоити ИНАДА
Казумаса ЙОКОЯМА
Original Assignee
Киссеи Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Киссеи Фармасьютикал Ко., Лтд. filed Critical Киссеи Фармасьютикал Ко., Лтд.
Publication of RU2017132689A publication Critical patent/RU2017132689A/ru
Publication of RU2017132689A3 publication Critical patent/RU2017132689A3/ru
Application granted granted Critical
Publication of RU2715606C2 publication Critical patent/RU2715606C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (7)

1. Fc-слитый белок, содержащий: (i) α-цепь высокоаффинного рецептора IgE; и
(ii) Fc-область IgG1, где
область фрагмента линкера между (i) и (ii) представляет собой аминокислотную последовательность, представленную в SEQ ID NO: 2.
2. Fc-слитый белок по п. 1, содержащий аминокислотную последовательность, представленную в SEQ ID NO: 3, или аминокислотную последовательность, содержащую делецию лизина (K) на C-конце аминокислотной последовательности, представленной в SEQ ID NO: 3.
3. Fc-слитый белок по п. 1 или 2, который представляет собой димер.
4. Fc-слитый белок по п. 3, где остатки цистеина в области фрагмента линкера образуют три дисульфидные связи.
5. Фармацевтическая композиция, содержащая в качестве активного ингредиента Fc-слитый белок по любому из пп. 1-4.
RU2017132689A 2015-02-20 2016-02-19 СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE RU2715606C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2015-032231 2015-02-20
JP2015032231 2015-02-20
JP2015-252231 2015-12-24
JP2015252231 2015-12-24
PCT/JP2016/054854 WO2016133197A1 (ja) 2015-02-20 2016-02-19 Fc融合高親和性IgE受容体α鎖

Publications (3)

Publication Number Publication Date
RU2017132689A true RU2017132689A (ru) 2019-03-20
RU2017132689A3 RU2017132689A3 (ru) 2019-08-15
RU2715606C2 RU2715606C2 (ru) 2020-03-02

Family

ID=56692248

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017132689A RU2715606C2 (ru) 2015-02-20 2016-02-19 СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE

Country Status (19)

Country Link
US (2) US10077297B2 (ru)
EP (1) EP3260469B1 (ru)
JP (1) JP6192862B2 (ru)
KR (2) KR20230132610A (ru)
CN (1) CN107207623B (ru)
AU (1) AU2016220766B2 (ru)
BR (1) BR112017017609A2 (ru)
CA (1) CA2976623C (ru)
ES (1) ES2806205T3 (ru)
HK (1) HK1244016A1 (ru)
IL (1) IL253832B (ru)
MX (1) MX2017010359A (ru)
PL (1) PL3260469T3 (ru)
PT (1) PT3260469T (ru)
RU (1) RU2715606C2 (ru)
SG (1) SG11201706543UA (ru)
TW (1) TWI691512B (ru)
WO (1) WO2016133197A1 (ru)
ZA (2) ZA201706281B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7127859B2 (ja) * 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
WO2019135666A1 (ko) * 2018-01-08 2019-07-11 주식회사 프로젠 Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물
SG11202005858WA (en) * 2018-01-08 2020-07-29 Gi Innovation Inc Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same
JP7041272B2 (ja) * 2018-01-12 2022-03-23 ジーアイ・イノベイション・インコーポレイテッド プロバイオティクスおよびIgEへの結合親和性を有するポリペプチドを含む組成物およびその使用
WO2021006603A1 (ko) * 2019-07-08 2021-01-14 주식회사 프로젠 신규 알러지 질환 치료용 약학적 조성물
WO2021006375A1 (ko) * 2019-07-08 2021-01-14 (주)지아이이노베이션 Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물
BR112022000246A2 (pt) * 2019-07-08 2022-02-22 Gi Innovation Inc Dímero polipeptídico com elevado teor de ácido siálico, compreendendo o domínio extracelular da subunidade alfa do receptor fc de ige e composição farmacêutica compreendendo o mesmo

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
WO2008028068A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
WO2008099188A1 (en) 2007-02-15 2008-08-21 Astrazeneca Ab Binding members for ige molecules
PL2132230T3 (pl) * 2007-03-22 2014-09-30 Genentech Inc Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną
KR101631454B1 (ko) 2008-10-31 2016-06-17 가부시키가이샤 한도오따이 에네루기 켄큐쇼 논리회로
CN101633698B (zh) 2009-08-26 2011-12-21 北京精益泰翔技术发展有限公司 一种免疫融合蛋白及其编码基因与应用
MX344935B (es) 2009-10-26 2017-01-11 Genentech Inc Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
WO2011103584A2 (en) * 2010-02-19 2011-08-25 Xencor, Inc. Novel ctla4-ig immunoadhesins
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE

Also Published As

Publication number Publication date
RU2715606C2 (ru) 2020-03-02
AU2016220766A1 (en) 2017-08-31
PL3260469T3 (pl) 2020-11-02
KR20170120579A (ko) 2017-10-31
US20180312566A1 (en) 2018-11-01
KR20230132610A (ko) 2023-09-15
ZA201706281B (en) 2019-04-24
AU2016220766B2 (en) 2021-03-04
NZ734482A (en) 2022-03-25
ES2806205T3 (es) 2021-02-16
TW201636373A (zh) 2016-10-16
EP3260469A1 (en) 2017-12-27
US10077297B2 (en) 2018-09-18
MX2017010359A (es) 2018-01-23
BR112017017609A2 (pt) 2018-05-08
IL253832B (en) 2021-05-31
WO2016133197A1 (ja) 2016-08-25
CN107207623A (zh) 2017-09-26
KR102602539B1 (ko) 2023-11-15
JP6192862B2 (ja) 2017-09-06
CA2976623A1 (en) 2016-08-25
ZA201804191B (en) 2019-09-25
HK1244016A1 (zh) 2018-07-27
CN107207623B (zh) 2021-01-29
IL253832A0 (en) 2017-09-28
JPWO2016133197A1 (ja) 2017-06-15
RU2017132689A3 (ru) 2019-08-15
US20180044402A1 (en) 2018-02-15
TWI691512B (zh) 2020-04-21
SG11201706543UA (en) 2017-09-28
EP3260469B1 (en) 2020-05-13
EP3260469A4 (en) 2018-08-22
PT3260469T (pt) 2020-07-29
CA2976623C (en) 2023-03-21

Similar Documents

Publication Publication Date Title
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
HRP20231496T1 (hr) Cistein proteaza
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
JP2018510622A5 (ru)
JP2016526909A5 (ru)
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
JP2017512063A5 (ru)
JP2018506286A5 (ru)
HRP20190689T1 (hr) Muteini suznog lipokalina koji vežu il-4r alfa
JP2017527272A5 (ru)
JP2017528419A5 (ru)
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
RU2017101436A (ru) Mic-1 слитные белки и их применение
AR102522A1 (es) Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a
RU2021134101A (ru) Модифицированная j-цепь
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
WO2015188132A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
NZ596787A (en) Growth hormone polypeptides and methods of making and using same
EA201890220A1 (ru) Вакцина против rsv
RU2015110250A (ru) ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
WO2015023891A3 (en) Factor viii-xten fusions and uses thereof
BR112017001340A2 (pt) vacinas antidengue e anticorpos
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου